Hématologie Myélome
MIDAS (IFM 202-02)
MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study.
Paris
FREDERIQUE KUHNOWSKI